EGLN3 and anemia (phenotype): Because PHD3 is the key enzyme regulating HIF activity in response to pO2, inhibiting PHD3 is an attractive target for pharmaceuticals to treat diseases related to HIF up-regulation, such as myocardial infarction, stroke, and anemia, among others [9]–[11].